Company Filing History:
Years Active: 2022-2025
Title: Innovations by Kara Carter in Chikungunya Virus Research
Introduction
Kara Carter is an accomplished inventor based in Bridgewater, NJ (US). She has made significant contributions to the field of virology, particularly in the development of therapeutics for Chikungunya virus (CHIKV). With a total of two patents to her name, her work is pivotal in addressing the challenges posed by this infectious disease.
Latest Patents
Kara Carter's latest patents include innovative solutions aimed at combating CHIKV. The first patent focuses on anti-CHIKV antibodies and their uses. This invention concerns antibodies and antigen-binding fragments that specifically bind to and neutralize the Chikungunya virus. These engineered antibodies are designed to develop therapeutics for treating CHIKV disease or preventing CHIKV infection. The invention also encompasses pharmaceutical compositions that utilize these antibodies for effective prevention and treatment.
The second patent is centered on anti-CHIKV monoclonal antibodies directed against the E2 structural protein. Similar to her first patent, this invention involves antibodies that specifically target and neutralize CHIKV. The goal is to create therapeutics that can effectively treat or prevent CHIKV disease, along with pharmaceutical compositions that incorporate these antibodies.
Career Highlights
Kara Carter is currently associated with Sanofi, a leading global healthcare company. Her role at Sanofi allows her to leverage her expertise in virology and antibody engineering to contribute to the development of innovative treatments. Her work is crucial in the ongoing fight against viral diseases, particularly those that pose significant public health risks.
Collaborations
Kara collaborates with talented professionals in her field, including Cendrine Lemoine and Marie Mandron. These collaborations enhance the research and development process, fostering innovation and the sharing of ideas.
Conclusion
Kara Carter's contributions to the field of Chikungunya virus research through her patents and work at Sanofi highlight her dedication to advancing medical science. Her innovative approaches to developing therapeutics are essential in the fight against infectious diseases.